BERKELEY, CA--(Marketwired - Dec 29, 2014) - Dynavax Technologies Corporation (
"This credit facility provides us access to up to $40 million of non-dilutive funding that can be used to support development and pre-commercialization activities for HEPLISAV-B, clinical trials of our cancer immunotherapeutic product candidate, SD-101, and advancement of our research programs," said Eddie Gray, CEO of Dynavax.
Further information with respect to the loan facility with Hercules is contained in a Current Report on Form 8-K to be filed on December 29, 2014 by Dynavax with the Securities and Exchange Commission.
About Dynavax
Dynavax, a clinical-stage biopharmaceutical company, uses TLR biology to discover and develop novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidate is HEPLISAV-B, a Phase 3 investigational adult hepatitis B vaccine. For more information visit www.dynavax.com.
About Hercules Technology Growth Capital, Inc.
Hercules Technology Growth Capital, Inc. (
Contact Information:
Contact:
Michael Ostrach
Chief Business and Principal Financial Officer
510-665-7257